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Figure 1: Factors Contributing to 
Justice-Involvement 
Matthew Epperson, Nancy Wolff, Robert Morgan, 
William Fisher, B. Christopher Freuh & Jessica 
Huening. The Next Generation of Behavioral Health and 
Criminal Justice Interventions: Improving Outcomes by Im-
proving Intervention, Center for Behavioral Health 
Services and Criminal Justice Research (2011). 
tween health outcomes and criminal 
activity.  Health problems influence 
reentry outcomes including housing, 
employment, family relationships, sub-
stance use, and recidivism.16 Additional-
ly, many predictors of poor health out-
comes are also predictors for criminal 
activity.17   Health care needs to be ad-
dressed in the reentry planning process, 
with a focus on continuity of care and 
linkages to appropriate services. 18 
 Healthcare reform embraces a 
holistic approach to healthcare in sever-
al ways as legislated in the Patient Pro-
tection and Affordable Care Act 
(PPACA) signed into law by President 
Obama on March 23, 2010.  Communi-
ty health workers will encourage preven-
tative health through education, guid-
ance, and outreach in medically under-
served racial and ethnic minority com-
munities.19 Information will be provided 
regarding the promotion of healthy be-
 
confronted with the need to obtain what 
is necessary in order to survive and func-
tion: housing, employment, healthcare, 
and other services.8  This is often in addi-
tion to managing significant health prob-
lems such as substance use and mental 
health disorders.9 
 Most returning offenders have 
limited to no savings, no immediate ac-
cess to unemployment benefits, and no 
job prospects.10  Additionally, up to 90% 
of individuals who are incarcerated at 
local and county jails have no insurance 
of any kind.11  Ex-offenders face serious 
challenges finding a job in an increasingly 
competitive job market both due to their 
disclosed ex-offender status and general 
decreased lack of skills and experience.  
Indeed, up to 60% of individuals contin-
ue to be unemployed at a legitimate job 
one year after their release.12 
 It is no surprise that the time 
immediately following release is a critical 
period with a significantly increased risk 
of morbidity.  In a Washington state 
study conducted from 1999-2003, the 
risk of death among former inmates dur-
ing their first two weeks of release was 
found to be 12.7 % higher than among 
other state residents of the same age, 
race, and sex.13   There is also a consider-
ably higher prevalence of cardiovascular 
disease, cancer, liver disease, suicide, 
homicide, HIV, diabetes, and overdose 
among individuals released from prison 
than their incarcerated counterparts.14 A 
lack of health insurance, difficulty obtain-
ing care, the high prevalence of mental 
illness, and the detrimental psychological 
stress of reentry contributes to these 
problems.15 
 A coordinated holistic approach 
to care is most appropriate given the ar-
ray of problems the offending population 
faces, and the dynamic relationship be 
Healthcare Reform and  
Coordinated Care Through  




 Corrections in the United 
States is characterized by high rates of 
recidivism and an enormous amount of 
spending.  Nearly 95% of those incar-
cerated will reenter back into society; 
however, the vast majority of released 
individuals continue to cycle through 
the legal system throughout most of 
their lives.1 A staggering $75 billion 
dollars was spent in 2008 among feder-
al, state, and local governments, with 
the majority of that money used directly 
for incarceration costs.2   
 A complex set of individual 
and environmental factors impacts the 
health status of the offending popula-
tion.3  A lack of preventative care, a 
lack of coordinated and consistent care, 
and the effects of repeated and/or sus-
tained periods of incarceration further 
complicates these factors.  While re-
turning offenders are heavy consumers 
of healthcare services, treatment for 
their health conditions declines after 
reentering the community.4  Emergency 
room visits and hospitalizations provide 
the primary source of care for the of-
fending population.5  The result is ulti-
mately individuals reentering into the 
community receive acute, fragmented 
care for chronic problems.6  
 Reentering into the communi-
ty is often an extremely confusing and 
stressful period of time fraught with 
new challenges.  Most individuals enter-
ing and leaving prisons come from, and 
are returned to, poor minority commu-
nities.7  After being removed from their 
community for a substantial period of 
time, reentering offenders are suddenly 
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haviors, discouragement of risky health 
behaviors, guidance on enrolling in an 
applicable health plan, as well as refer-
rals to community based programs that 
minimize fragmented care.20 The Sec-
retary of Health and Human Services is 
also responsible for planning and im-
plementing a national outreach and 
education campaign to increase public 
awareness of health across the lifespan, 
such as the provision of information 
related to: utilizing health services to 
reduce health disparities and mitigate 
chronic disease, preventative services, 
healthy behaviors and proper nutrition, 
the negative effects of smoking and 
obesity, disease screening, health pro-
motion, and disease prevention to 
healthcare providers participating in 
Federal programs.21 
 Additionally, PPACA dramati-
cally expands Medicaid to include 
those individuals under the age of 65 at 
or below 133% of the federal poverty 
level in 2014.22  This will include a sub-
stantial proportion of offenders return-
ing to the community as those with the 
fewest financial resources often wind 
up in the criminal justice system.23  The 
Center for Medicare and Medicaid In-
novation will undertake many efforts 
to streamline patient care and reduce 
expenditures through information 
technology and the development of 
new patient care models.24 The crea-
tion of community based medical 
homes and teams will be encouraged 
through grant funding. 25  These teams 
will assist community members and 
small-group practices treating chronic 
conditions in managing and coordinat-
ing care by connecting individuals to 
appropriate services and assisting with 
facilitating payments to providers. 26 
 Starting January 1, 2011, 
PPACA has created a state option for 
the establishment of “health homes” for 
those on Medicaid with chronic prob-
lems.27 Participation in the option is 
voluntary, however, matching federal 
grants are provided for the planning and 
development of the health homes, and 
States are reimbursed 90% of the Feder-
al Medical Assistance Percentage for the 
first eight fiscal quarters.28 Health homes 
provide comprehensive treatment and 
care in part through integrating and co-
ordinating services with other specialists 
and providers such as clinics, behavioral 
health services, and substance abuse 
services.29 Medicaid benchmark benefits 
have also been revised to include mini-
mum essential coverage to include parity 
for mental health and addiction disorder 
treatment if care is provided through a 
managed care organization.30  
 To be effective for the offend-
ing population, however, education and 
coordination of traditional continuous 
care is likely to be just the beginning.  
To maximize improved health out-
comes, the individual and environmental 
factors associated with criminality must 
be targeted and addressed (See Figure 
1).31 Individual factors are unique to the 
person and include mental illness, addic-
tion, poverty, and antisocial beliefs and 
attitudes.32  Environmental factors are 
conditions that increase risk of criminal 
justice involvement such as drug culture, 
homelessness, unemployment, violence, 
and prostitution.33 Stress and trauma 
further aggravate the individual and the 
environmental factors associated with 
criminal behavior, as well as increases 
the likelihood that individuals will be-
have in ways harmful to themselves and 
the community.34 
Policymakers can no longer 
afford to ignore the detrimental conse-
quences of an overinflated prison popu-
lation, the socioeconomic and racial 
disparities to accessing and obtaining 
appropriate healthcare, and the impact 
of individual and environmental factors 
on criminal thinking and behavior. 35  
The correctional system in the United 
States is overwhelmed by a high number 
of offenders. The prison-industrial com-
plex is more likely to be a site of trauma, 
rape and violence than a genuine source 
of rehabilitation.36 Given the harms it is 
likely to impose on prisoners during 
their time under incarceration, it is im-
perative that it contribute to assuring 
continuous post-incarceration care.  
 There is no simple and straight-
forward solution to providing effective 
and affordable healthcare to ex-
offenders.  Healthcare reform provides 
states with the framework to adopt ho-
listic diversion and reentry practices in 
order to improve health outcomes for 
the offending population.  The efforts 
of recent trends in holistic legislation 
will be diminished, however, if the caus-
es and effects of criminal thinking and 
behavior are not incorporated into case 
management, treatment plans, education 
outreach, and assistance provided with 
dollars allocated for healthcare spend-
ing.  If these factors are successfully 
addressed then not only will health out-
comes have the opportunity to improve, 
but so will the costs incurred by the 
correctional system through effective 
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Regulating Health 
 Two recent studies, one led by 
Yoshihiro Kawaoka and the other by 
Ron Fouchier provide a model of the 
virus that is transmissible in ferrets.5 
The Fouchier paper reports on the 
transmissibility of the full H5N1 virus, 
while the Kawaoka paper “provides a 
method for producing a transmissible 
H5N1 reassortant virus.”6 The H5N1 
strain used in the research was found to 
be highly communicable between mam-
mals, and the ferret is considered the 
best available model of the flu virus in 
humans.7 
The two studies could be replicated to 
create a highly transmissible virus that 
would pose serious threats to biosecuri-
ty.8 For that reason, calls for the studies 
to remain unpublished or be redacted 
became plentiful.9 On February 17, 
2012, the World Health Organization 
(WHO) convened an expert meeting to 
discuss the issue of what portions of the 
studies should be published.  Although 
they reached the decision that both the 
Kawaoka and Fouchier studies should 
be published in full, the meeting did not 
address the larger question of how to 
balance the threat of bioterrorism with 
the need for scientific research, and 
whether or not publication of medical 
research should be regulated.10 It is not 
necessary to answer this larger question 
at this time.   
 This article argues that the ben-
efits of publishing this Avian Flu re-
search greatly outweigh the risk of bio-
terrorism.  Disallowing or severely regu-
lating the publication of this research 
would be a greater risk to public health 
than the threat of bioterrorism.  For the 
following three reasons this research 
should be published in full: (1) studying 
the flu virus in ferrets does not dictate 
exactly how the flu will manifest in hu-
mans; (2) studying and understanding 
Avian Flu is important for early detec-
tion and prevention of the disease as 
well as creating vaccinations, especial-
ly if it were to be used as a biological 
weapon; and (3) past scientific re-
search that has posed a risk of bioter-
rorism has been published with no 
significant public health detriment.  
 
Influenza Behavior in Ferrets is not 
an Exact Replica of Influenza Behav-
ior in Humans 
 Two main differences in the 
manifestation of the Avian Flu exist 
between ferrets and humans: its com-
municability and its severity.11  The 
communicability of this strain in fer-
rets has shown to be much greater 
than that in humans, but more re-
search is required to know for sure 
whether the strain would be as trans-
missible in humans as it is in ferrets.12 
Because influenza is always mutating, 
it is not impossible that the strain 
would mutate naturally into the strain 
created by these studies.13 Since the 
advancement of scientific research is 
largely based upon building on previ-
ous published research, imposing 
strict regulation on its publication 
would prevent researchers from being 
able to understand how the communi-
 
Should regulations on the  
publication of recent Avian Flu  




 Scientific research has long 
been a boon to our society.  It has 
lengthened human life expectancy, 
eradicated deadly communicable dis-
eases, and cured people of illnesses that 
previously would have been deadly.  
Nevertheless, with every scientific dis-
covery comes the potential for misuse.  
A transmittable strain of a deadly virus 
that falls into the wrong hands could 
lead to a pandemic, harming hundreds 
of thousands of people.  We saw the 
misuse of a biological agent on a small 
scale with Anthrax in 2001, and recent 
studies on the H5N1 virus (commonly 
referred to as Avian Flu) elicit the same 
fear of misuse, called the “dual-use” 
concern.1 
 Avian Flu is a virus that is 
highly contagious among poultry.2 
Though it is not usually found in hu-
mans, the virus can be transmitted 
from infected poultry to humans as a 
result of close contact.3 However, even 
humans infected with H5N1 do not 
generally pose a risk to other uninfect-
ed humans.4 
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cability of the disease could change 
as the virus mutates.  To prevent 
publication at this stage would be 
detrimental to the advancement of 
Avian Flu research.   
 Secondly, the strain of the 
virus appears to be less severe in 
ferrets than it is in humans.14 The 
Centers for Disease Control and 
Prevention (CDC) states that 60% 
of people infected with the highly 
pathogenic form of the virus have 
died from the disease.15 However, 
only a minority of strains of H5N1 
is deadly in ferrets.16 More research 
is needed to understand how the 
virus will behave in humans and 
whether the severity of this strain of 
the Avian Flu will mirror the mani-
festation in ferrets, or be more se-
vere. Although ferrets provide a 
viable framework for understanding 
how influenza will behave, it is not 
an exact model.  Preventing or reg-
ulating the publication of Avian Flu 
research, as some members of the 
scientific community have called for, 
would hinder scientists’ ability to answer 
the questions of human communicability 
and severity, posing a risk to public 
health if the virus were to naturally mu-
tate. 
 
We Must be Able to Detect, Contain and 
Prevent the Virus Should it become a 
Biological Weapon 
 An outbreak of Avian Flu could 
manifest in a number of ways.  Should 
Kawaoka and Fouchier’s research fall 
into the wrong hands, it is important that 
the scientific community have infor-
mation about how to detect, treat, and 
vaccinate against the virus.  Without pub-
lished research, we may be unable to find 
a way to treat or contain an Avian Flu 
pandemic if the flu mutates into a more 
communicable strain from human to 
human.  If such a strain develops and is 
spread, whether naturally or through an 
act of terror, there will be a large public 
health issue at hand.   
 In 2009, a worldwide out-
break of the H1N1 virus infected an 
estimated 61 million people.17 The 
virus was highly contagious and 
spread quickly, leading the WHO to 
declare it a pandemic.18 Following the 
outbreak of the virus, the response to 
the pandemic was evaluated, conclud-
ing that the H1N1 pandemic 
“exposed vulnerabilities in public 
health capacities, limitations of scien-
tific knowledge…and challenges in 
the communications among experts, 
policymakers and the public.”19 The 
evaluation concludes, “The world is ill
-prepared for a severe influenza pan-
demic.”20 In order to rectify this, the 
WHO makes a number of recommen-
dations including, but not limited to, 
“sharing of viruses and access to vac-
cines,” “expanding influenza vaccine 
production capacity,” and taking 
“measures to detect and promptly 
identify potential pandemic influenza 
viruses.”21  
 In order to accomplish these 
goals and be better prepared for an 
Avian Flu pandemic, research must be 
conducted, and studies must be pub-
lished and shared among the scientific 
community.  Prohibiting the Fouchier 
and Kawaoka studies from being pub-
lished in full would create a great risk 
to public health, resulting unprepared-
ness to combat an outbreak of the 
virus.  The more time and opportuni-
ty that the scientific community has to 
research and understand the way that 
Avian Flu can mutate and spread, the 
better prepared it will be to deal with 
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Scientific Research that has Posed a Risk 
of Bioterrorism has Been Published in 
the Past 
 Advances in medical research 
often ignite concerns of misuse, a phe-
nomenon often called the “dual use con-
cern.”22 In the context of Avian Flu, the 
dual-use concern is whether the biosecu-
rity risks of publishing the Fouchier and 
Kawaoka studies in full outweigh the 
benefits of disseminating the research.23  
History has shown that publication of 
studies that pose a risk of bioterrorism is 
possible without the research being mis-
used. For example, a study detailing the 
reconstruction of the 1918 influenza 
virus was published in full, and the 
threat of bioterrorism has not come to 
fruition.24  In addition, the results of 
extensive research about the smallpox 
virus, as well as reserves of the smallpox 
virus have been around for almost 30 
years and neither the research, nor the 
reserves of the virus, has been misused.25 
 In fact, there have been very 
few incidents of misuse of medical re-
search in the United States.  One such 
incident occurred in 1984 when a reli-
gious group used Salmonella typhimuri-
um to contaminate restaurant salad bars 
in Oregon.26  The group, running a legiti-
mate clinical laboratory, used books that 
described “bacteria and other methods 
to make people ill,” and learned to cul-
ture the bacteria with the help of a labor-
atory technician.27 The misuse of the 
published results, and the aid from a 
member of the scientific community led 
to an estimated 751 infections, but there 
were no fatalities.28 Considering these 
results, it is important to be cautious of 
bioterrorism, but the threat is not greater 
than that to public health that exists by 
not publishing research results, including 
those from the recent studies of Avian 




 For the foregoing reasons, the 
publication of this Avian Flu research 
should not be strictly regulated or pro-
hibited.  Though the publication of sci-
entific research often carries the dual-use 
concern, there have been relatively few 
instances of misuse in comparison to the 
vast amount of research that is pub-
lished.  Because the Kawaoka and 
Fouchier studies of Avian Flu in ferrets 
are not exact models of how the virus 
will behave in humans, and because there 
is a need to develop vaccines and ways to 
detect the virus if it were to mutate or be 
released in an act of bioterrorism, the 
threat of bioterrorism does not outweigh 
the public health interest in publication 
of results. ☼  
 
"THE MORE TIME AND OPPOR-
TUNITY THAT THE SCIENTIFIC 
COMMUNITY HAS TO RESEARCH 
AND UNDERSTAND THE WAY 
THAT AVIAN FLU CAN MUTATE 
AND SPREAD, THE BETTER PRE-
PARED IT WILL BE TO DEAL WITH 
BIOTERRORISM, OR A NATURAL 
MUTATION OF THE VIRUS." 
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By Ryan Upchurch 
Ryan.upchurch@student.shu.edu 
 
 In April 2010, Kumud Majum-
der suffered every parent’s worst night-
mare when he lost his son and only 
child, Arya, to leukemia.1  Arya, whom 
Kumud described as “an angel who 
transformed my life” was only eleven 
years old when he passed.2  His death 
was in part hastened by the inability to 
find a bone marrow match for trans-
plant.  Unfortunately, stories resembling 
Kumud’s are far too commonplace.  
Over 100,000 Americans are diagnosed 
annually with serious blood and bone 
marrow disorders, with leukemia being 
the most prominent diagnosis.3 Many of 
these individuals require a transplant of 
bone marrow cells to combat their par-
ticular malady.   
 
Difficulty of Bone Marrow Matches 
 Finding matches for bone mar-
row recipients is a difficult proposition 
because there are various types of pro-
teins present on bone marrow stem 
cells.  Family members generally offer 
the best probability for a match, but 
even then the estimated success rate of 
30% is paltry at best.4 The difficulty in 
matching blood stem cells has led to 
striking statistics for those in need.  An 
estimated 40,500 adults are diagnosed 
with leukemia annually as well as anoth-
er 3,500 children.5 Anywhere between 
2,000 and 3,000 Americans die every 
year from a failure to achieve a suitable 
bone marrow match for their blood-
based illness.6 
 Statistics illustrate distinctive 
success rates for people of different 
racial groups.  Matches are rare for 
those of mixed-race parentage and Afri-
can American descent, as they tend to 
possess a combination of African, Cau-
casian, and Native American genes.7 
Caucasian patients are successfully 
matched roughly 70% of the time, but 
this number drops to only about 40% 
for Americans of African descent.8 A 
potential means of increasing the num-
ber of matches is to possibly enlarge the 
donor pool by offering some form of 
compensation.  Until the Flynn v. Holder 
decision, this was presumed to be pro-
hibited by the National Organ Trans-
plantation Act (“NOTA”).9 
Flynn v. Holder: Legalizing Compensation 
for the Apheresis Method of Donation 
 
 On December 1, 2011, the 
Court of Appeals for the Ninth Circuit 
held in Flynn v. Holder that compensation 
for bone marrow stem cells derived 
from the “peripheral blood stem cell 
apheresis method” (“apheresis”) was 
legal.10 Additionally, the Court con-
firmed that compensation was still pro-
hibited for donation of bone marrow 
through the more antiquated method of 
aspiration.11 
 The Court considered the dis-
tinctions between the two methods of 
marrow donation, apheresis and aspira-
tion, in arriving at its ruling.  Aspiration 
was described by the Court as a 
“painful, unpleasant procedure” in 
which thick needles are inserted into the 
cavities of the anesthetized donor’s 
bones in order to extract the soft, fatty 
substance from within commonly 
known as bone marrow.12 This proce-
dure for bone marrow donation was in 
place in 1984 when Congress enacted 
the National Organ Transplant Act 
(NOTA), and it accounts for about one 
third of current donations.13   
 However, the newer method of 
apheresis has been developed since 
then.  For apheresis, the donor is first 
injected with granulocyte colony-
stimulating factor medication for five 
days prior to the procedure, which in-
creases the amount of blood stem cells 
that exit from the marrow and enter 
into the bloodstream.14 Afterwards, a 
collection needle is placed into the do-
nor’s vein.15 The apheresis machine sep-
arates out the blood stem cells and the 
left over fluid is injected back into the 
donor.  The stem cells taken from the 
donor will be replaced naturally by his 
or her body within three to six weeks.16 
The apheresis method of extraction is 
more common now, being used in 
about two thirds of all donations.17 
 On its face, NOTA prohibits 
any compensation for bone marrow.18 
However, the Ninth Circuit did not be-
lieve that the statute was applicable to 
the apheresis method of bone marrow 
donation because the Court likened the 
apheresis method to an ordinary blood 
donation.19 NOTA’s scope specifically 
excluded blood and its derivatives.20  As 
the Court acknowledged, the only dif-
ference between an ordinary blood do-
nation and a donor undergoing the 
apheresis method is that the latter in-
volves the donor sitting for longer as 
well as the apheresis machine separating 
stem cells from the blood.21 When the 
apheresis machine is used to sort and 
 
Flynn v. Holder: A Slippery Slope Towards Organ Compensation? 
Whole blood enters the centrifuge (1) and 
separates into plasma (2), leukocytes (3), 
and erythrocytes (4). Selected components 
are then drawn off (5).  
collect plasma or platelets it is referred to 
as a “blood donation” or a “blood plasma 
donation.”22  When it is used to separate 
out blood stem cells, it is commonly 
known as a “bone marrow donation.”23 
Apheresis is a “Bone Marrow Donation” 
in Name Only 
 
 With respect to the newer apher-
esis method, the question before the 
court was whether a procedure common-
ly referred to as a “bone marrow dona-
tion” actually meant that bone marrow 
itself was involved.  Under the apheresis 
method, none of the soft, fatty substance 
that is extracted through aspiration is 
present.24 Rather, the apheresis machine 
merely separates blood stem cells from 
the blood that is extracted.25  For the 
Court, the critical components were the 
actual material separated out and the loca-
tion from which the material came.  The 
donor would be providing his or her 
blood stem cells, not their bone marrow.  
Furthermore, these blood stem cells 
would come from the blood, not from 
within the cavities of the donor’s bones.  
If compensating donors for their stem 
cells through this method was banned, 
the Court reasoned then that all compen-
sated blood donations must be outlawed 
as well.  However, the Senate Report had 
specifically excluded blood from the lan-
guage of the statute.26 
 NOTA provides that “the term 
‘human organ’ means the human 
(including fetal) kidney, liver, heart, lung, 
pancreas, bone marrow, cornea, eye, 
bone, and skin or any subpart thereof and 
any other human organ (or any subpart 
thereof, including that derived from a 
fetus) specified by the Secretary of Health 
and Human Services by regulation.”27 
Subsequently, the government raised the 
issue as to whether the blood stem cells 
fell under the statutory language of “or 
any subpart thereof” in reference to not 
just organs in their entirety but any sub-
part as well.28 These blood stem cells do 
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after all originate in the bone marrow 
before naturally moving into the blood-
stream.  Because the distance between 
actual bone marrow and the blood-
stream is great enough, the Court found 
that this argument lacked merit.29 Addi-
tionally, the drafters of NOTA could 
not have had the apheresis in mind be-
cause it had not yet been developed.30 
 
A Slippery Slope Appears Likely  
 Perhaps the first thought to 
arise from this decision is that of the 
proverbial slippery slope.  Opponents of 
organ commodification may be wary 
that the Ninth Circuit’s interpretation 
could lead down a path towards black 
markets, harvesting of organs, and vast 
economic inequalities.  On the other 
hand, NOTA is explicit in the limita-
tions placed on remuneration for most 
body parts.  Human kidneys, livers, 
hearts, lungs, pancreas and the ever im-
portant “any subpart thereof” are just 
some of the organs prohibited.31 The 
Court’s holding was much narrower 
than it may have appeared at first 
glance.32 The issue then is whether the 
Flynn decision could in any way lead 
down a slippery slope towards relaxing 
or overruling NOTA in the future. 
 Generally a slippery slope can 
be thought of as a particular decision 
(decision A), which may be appealing 
now, but increases the probability that 
another broader decision (decision B) 
will be accepted later.33 Due to its 
broader scope, decision B is usually op-
posed by some who initially wanted A.34  
However, many frameworks exist for 
different slippery slope arguments, and 
often times slippery slopes are com-
posed of more than just two decisions.  
A slippery slope made up of three dis-
tinct decisions, or points, is a simple 
example of a multi-peaked preference 
slippery slope.35 
 The multi-peaked preference 
slippery slope provides the most plausi-
ble framework for the issue at hand.  In 
this argument, the middle position is the 
least desirable of the three while either 
extreme offers a preferable option.36 
There are several subsets of multi-
peaked preference slippery slopes.  One 
is the basic equality version, in which 
both extremes (A & C) are preferred to 
the middle position (B) because getting 
to position B without then reaching 
position C may be unfairly discriminato-
ry.37 In applying this here, position A 
represents the way things were prior to 
Flynn, position B represents the current 
state of affairs legalizing compensation 
under apheresis, and position C repre-
sents removing the ban on compensa-
tion for all organs.  The supporters of 
position B are happy with the ruling, but 
many of them hope to see a move from 
position B to position C as well.  Posi-
tion C’s supporters are generally com-
prised of those afflicted by diseases to 
organs within NOTA’s scope.  For ex-
ample, more than 83,000 Americans are 
currently on the waiting list for kid-
neys.38 Roughly 13 of them die every 
day.39 It may seem unjust to some that 
an individual has a potentially larger 
donor pool from which to find a match 
based upon the particular part of their 
body that is afflicted.  Now that position 
B has been legalized, if a large enough 
percentage of people believe it is unjust 
"IN A SMALL BUT HIGHLY SUC-
CESSFUL STANFORD UNIVERSITY 
STUDY, DONORS OF KIDNEYS 
THEN PROVIDED THEIR BLOOD 
STEM CELLS FOR A BONE MAR-
ROW TRANSPLANT TO THE SAME 
PATIENT.  EIGHT OF THE TWELVE 
PATIENTS WERE SUBSEQUENTLY 
FREED FROM THEIR NEED FOR 
LIFE-LONG IMMUNOSUPPRES-
SANT MEDICATIONS..." 
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to not then reach position C, we could 
see a slippery slope.  Nevertheless, posi-
tion C might have to eventually be 
reached within the legislature given the 
broad scope of NOTA in limiting judi-
cial interpretation. 
 Kidney transplants provide an 
interesting scenario to demonstrate the 
inequality of not moving from position 
B to position C.  As is clear from NO-
TA, the donor offering their kidney can-
not be compensated.40 Yet, in an admit-
tedly small but highly successful Stan-
ford University study, donors of kidneys 
then provided their blood stem cells for 
a bone marrow transplant to the same 
patient.41 Eight of the twelve patients 
were subsequently freed from their need 
for life-long immunosuppressant medi-
cations, which are used post-
transplantation to prevent the donated 
organ from being rejected.42 The immu-
nosuppressant medications are expen-
sive and include severe possible side 
effects.43 One estimate places the price 
of such medications at anywhere be-
tween $2,000 and $4,000 per month, 
although insurance or Medicare can be 
used to offset some of this cost.44 
 The donor would still be ineli-
gible for compensation after donating 
their kidney.  However under Flynn, the 
donor could be compensated for their 
donated blood stem cells, which then 
liberate the recipient from expensive 
and often dangerous medications.  This 
scenario, and the differing likelihoods of 
finding a donor match, serves as the 
best examples that we may be beginning 
down an equality slippery slope towards 
some form of organ compensation.    
      
Conclusion      
 
 The Flynn decision is a monu-
mental step forward for those afflicted 
by diseases of the blood or bone mar-
row.  By legalizing compensation for 
donation through apheresis, the chances 
are increased that the donor pool will be 
expanded and many more matches can 
be made.  This is especially true for 
mixed race and African American pa-
tients whose genetic makeup is more 
difficult to match for these kinds of 
transplants.    
 However, it may be premature 
to think that this will lead to any imme-
diate change to the statutory construc-
tion.  NOTA has the same effect it has 
had since 1984 and the legislature could 
even choose to simply add in “blood 
stem cell apheresis” to the statute if it so 
desired.45 Perhaps in the near future, 
regenerative medicine will alleviate the 
need for most organ transplants as pa-
tients can have the requisite organ 
grown from their own stem cells.46 A 
revitalized debate over organ commodi-
fication stemming from this decision is 
an important step for a slippery slope, 
though.   
 At any rate, Flynn is effectual 
and positive change and should be cele-
brated as such.  It is only when Flynn is 
assessed in relation to other organs that 
it could be dismissed as presently being 
too narrow.  Successful implementation 
of recompense for blood stem cells 
could still serve as a case study for those 
organs that remain prohibited by NO-
TA.  For now, it may not initially appear 
that Flynn will lead to broader compen-
sation, but one often cannot see where a 
slippery slope began until one has 
reached the bottom. ☼ 
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